## Amendments to the Claims:

The following listing of claims replaces all prior versions and listings of claims in this application.


## **Listing of Claims**

. :.

Claim 1 (original). A crystalline bicalutamide of form II.

Claim 2 (original). The bicalutamide according to claim 1, having an IR absorbance peak at 847 cm<sup>-1</sup> +/- 5 cm<sup>-1</sup>.

Claim 3 (currently amended). The bicalutamide according to claim 1, having an IR absorbance spectra substantially as shown below: in figure 4.




Claim 4 (original). The bicalutamide according to claim 1, having an x-ray diffraction peak at an angle of about 25.9°.

Claim 5(original). The bicalutamide according to claim 4, having an x-ray diffraction peak at an angle of 25.85° +/- 0.05°.

Claim 6 (original). The bicalutamide according to claim 1, having x-ray diffraction peaks at angles of about 11.6°, 13.0°, 18.1°, 24.4°, 25.3-25.9°, 26.7°, 29.9° and 33.6°.

Claim 7 (original). The bicalutamide according to claim 1, having x-ray diffraction peaks at angles of about 11.6°, 13.0°, 16.2°, 18.1°, 24.4°, 25.3-25.9°, 26.7°, 29.9° and 33.6°.

Claim 8 (currently amended). The bicalutamide according to claim 1, wherein said bicalutamide has an x-ray diffractogram substantially as shown below: in figure 2.



Claim 9 (original). The bicalutamide according to claim 1, wherein said bicalutamide is racemic bicalutamide.

Claim 10 (original). The bicalutamide according to claim 1, wherein said bicalutamide is at least 90% pure form II bicalutamide.

Claim 11 (cancelled).

Claim 12 (cancelled).

Claim 13 (cancelled).

Claim 14 (original) A pharmaceutical composition comprising the bicalutamide of form II according to claim 1, and a pharmaceutically acceptable excipient.

Claim 15 (original). The pharmaceutical composition according to claim 14, wherein said composition is a unit dosc and said bicalutamide of form II is contained in an antiandrogenic effective amount.

Claim 16 (original). The pharmaceutical composition according to claim 15, wherein said composition is substantially free of form I bicalutamide.

Claim 17 (original). The pharmaceutical composition according to claim 14, wherein said pharmaceutically acceptable excipient is a carrier or diluent.

Claim 18 (original). The pharmaceutical composition according to claim 17, wherein said excipient is selected from the group consisting of calcium phosphates, microcrystalline cellulose, hydroxypropyl methylcellulose, lactose, and starches.

Claim 19 (original). The pharmaceutical composition according to claim 14, wherein said

composition is a solid oral dosage form.

Claim 20 (original). The pharmaceutical composition according to claim 14, wherein said composition is a solution or suspension.

Claim 21 (original). The pharmaceutical composition according to claim 14, which further comprises bicalutamide form I.

Claim 22 (original). The pharmaceutical composition according to claim 21, wherein the relative amount of bicalutamide form II is within the range of 0.1 - 99.9% based on the total weight of all forms of bicalutamide.

Claim 23 (withdrawn). A method for producing an antiandrogenic effect, which comprises administering an antiandrogenic effective amount of the bicalutamide according to claim 1 to a mammal in need thereof.

Claim 24 (withdrawn). A process, which comprises precipitating bicalutamide form II from a solution containing bicalutamide.

Claim 25 (withdrawn). The process according to claim 24, wherein said precipitation is carried out in the presence of seed crystals of bicalutamide form II.

Claim 26 (withdrawn). The process according to claim 24, wherein said precipitation

is carried out by lowering the temperature of the bicalutamide solution and/or contacting said bicalutamide solution with a contrasolvent.

Claim 27 (withdrawn). The process according to claim 24, wherein said precipitation occurs at a temperature of 35°C or higher.

Claim 28 (withdrawn). A process which comprises heating an amorphous bicalutamide to form one or more crystals of bicalutamide form II.

Claim 29 (cancelled).